Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered over 21 Days with Lopinavir-Ritonavir in Human Immunodeficiency Virus Type 1-Infected Subjects

The purpose of this study was to describe the plasma pharmacokinetics (PK) of elvucitabine at different doses when administered daily or every other day for 21 days with lopinavir-ritonavir (Kaletra) in human immunodeficiency virus (HIV)-infected subjects. Three different dosing regimens of elvucita...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Colucci, Philippe, Pottage, John C., Robison, Heather, Turgeon, Jacques, Schürmann, Dirk, Hoepelman, I. M., Ducharme, Murray P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2009
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2630663/
https://ncbi.nlm.nih.gov/pubmed/19015343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00907-08
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados